Arrowhead Pharmaceuticals Posts Strong Q1 2026 on REDEMPLO Launch and R&D Milestones
Event summary
- Arrowhead reported $264M in revenue for Q1 2026, up from just $2.5K a year earlier, driven by REDEMPLO launch.
- REDEMPLO received FDA approval and launched in the U.S., with over 100 prescriptions written since November 2025.
- Company closed $930M in concurrent public offerings and triggered a $200M milestone payment from Sarepta.
- Novartis deal brought $200M upfront for ARO-SNCA collaboration, with potential $2B in future milestones.
The big picture
Arrowhead's transition to commercial-stage is marked by REDEMPLO's approval and strong Q1 revenue. The company's strategic partnerships with Novartis and Sanofi, along with $930M in new capital, position it for aggressive pipeline expansion. Success will depend on maintaining clinical momentum while managing the operational complexity of commercialization.
What we're watching
- Commercial Execution
- Whether Arrowhead can sustain REDEMPLO's early prescription momentum and payer adoption.
- Pipeline Progress
- The pace at which obesity and CNS programs advance through clinical trials.
- Capital Allocation
- How Arrowhead deploys its strengthened balance sheet across R&D and potential acquisitions.
Our editorial coverage:
Related topics